Introduction
Candida and Aspergillus species are the most common aetiology of invasive fungal diseases (IFDs) in individuals admitted to ICUs. These fungal species can produce infections that range from nonlife-threatening superficial disorders to severe invasive disease involving any organ. According to a recent publication, Candida spp. cause around 80% of IFDs in patients in ICU settings while Aspergillus spp. cause between 1% and 20% of invasive mycoses depending on the group of patients. 1 Candida albicans remains the most common species of yeast responsible for both candidaemia (primary or secondary) and deep-seated candidosis (with or without secondary candidaemia). Other species of Candida are involved in 40% of cases, largely C. tropicalis, C. glabrata and C. parapsilosis; however, geographic and age-related differences in the causative Candida spp. have been noted. 2, 3 In non-neutropenic patients admitted to ICUs, most invasive mould infections are caused by members of the Aspergillus fumigatus species complex, although the epidemiology has shifted in recent years as other species of Aspergillus and other moulds have become progressively more prevalent. 4, 5 The aim of this article is to review the current recommendations for the diagnosis and treatment of IFD in the ICU setting and to explore whether there is a standard of care for this patient population. The text focuses mainly on the two most common IFDs that afflict non-neutropenic patients; candidaemia and invasive candidosis (IC), and invasive pulmonary aspergillosis (IPA).
Diagnosis of IFDs in the ICU setting
The recommendations for detecting IC and IPA in the ICU setting do not differ from the diagnostic standards used in other groups of patients. However, some unique challenges and considerations should be borne in mind when diagnosing critically ill patients with an IFD.
Diagnosis of invasive candidosis and candidaemia
The mortality of IC is significantly higher when patients are not rapidly and appropriately treated, 6 and that is why standards of care for this patient population have recommended prophylactic regimens or empirical treatments in many cases. However, current guidelines do not recommend antifungal prophylaxis apart from some exceptions and advise the ICU practitioner to use a more targeted treatment than the empirical strategy. 7, 8 Targeted therapy must be based on reliable diagnostic techniques that show good performance and are able to rapidly detect the pathogens. In addition, these techniques should be accessible and affordable for clinical laboratories. 9 Conventional microbiological tests continue to be the benchmark of the standards of care to diagnose candidaemia and IC. Microscopic examination and blood cultures of any normally sterile and non-sterile sites should be performed when IC is suspected. 9 However, the performance of traditional microbiological techniques is not very good. Sensitivity of blood cultures never exceeds 50%. 10 Blood cultures and other cultures are not techniques for rapid detection. The incubation time until growth detection and species identification is usually 72-96 h. The advent of technical novelties such as mass spectrometry (MALDI-TOF) 11 and molecular classification of Candida species by DNA-target sequencing 12 has significantly reduced the time for identification of fungal species, but it is still too long to reverse current trends of prescribing empirical antifungal treatment based on clinical symptoms and signs. 7 Because of the limitations of methods based on cultures, alternatives techniques have been developed to diagnose candidaemia and IC earlier by detection of fungal cell components. Table 1 summarizes the role of these alternative techniques in the diagnosis of candidaemia and IC.
Tests for serological fungal biomarkers such as (1-3) b-D-glucan (BDG), mannan antigen and anti-mannan antibody, and Candida germ tube antibody (CAGTA) are commercially available for the early diagnosis of IC. 1, 13 BDG quantification is an alternative technique for candidaemia and IC detection, and one that has the most clinical experience and the highest number of publications. It is included among recommendations in several guidelines. The BDG test is one of the European Organization for Research and Treatment of Cancer/Mycosis Study Group (EORTC/MSG) diagnostic criteria for invasive fungal infections.
14 ESCMID and the US FDA recommend BDG quantification for ruling out candidaemia or IC in adult patients at risk of infection due to its high negative predictive value. 9 Other techniques for the detection of biomarkers and specific antibodies seem to have lower performance for the detection of candidaemia and IC, and so they are not strongly recommended as standards of care. However, some studies have reported that the combination of detection of two or more biomarkers could be of clinical utility for early diagnosis of IC and could become the standard for targeted and preemptive therapy. 1, 13 The quantification of other fungal biomarkers, such as DNA detection by PCR, has been shown to be another strategy for the rapid detection of yeasts. There are multiple in-house procedures reported to show good performance, 15-17 but they are not validated in large cohorts of patients, multicentre studies and randomized clinical trials. 9 Thus, the strength of recommendation of most guidelines for DNA detection using PCR is that reported evidence moderately supports its clinical use.
Recently, the FDA has approved the T2 Candida magnetic resonance (T2MR) test. This technique combines PCR technology with nanoparticle-based hybridization. It allows the direct identification in blood of different Candida spp. even in cases of bloodstream infections that were missed by blood cultures. 18 A clinical study has reported that the T2MR test can improve care by shortening times to Candida detection and species identification compared with blood cultures, retaining sensitivity during antifungal therapy and rendering active candidaemia unlikely if results are negative. 19 In addition, antifungal susceptibility testing (AST) should be also regarded as a standard of care. AST must be recommended for patient management for all Candida strains isolated from blood and other deep sites. Reference procedures or validated commercial techniques should be used. 9 
Diagnosis of invasive pulmonary aspergillosis
The diagnosis of IPA is quite similar to detection procedures described in the IC section above. The standard of care for detecting IPA recommends the combined use of risk evaluation, radiographic pattern examination and microbiological techniques. 14, 20 The limitations of conventional microbiological techniques have led to the development of alternative methods based on the quantification of fungal components. Some of these alternative techniques have been validated for clinical use in immunocompromised patients, but seem to have lower performance in non-neutropenic individuals. 20 Recently, several European societies have published guidelines for the diagnosis and management of Aspergillus diseases. 21 The interested reader is referred to those guidelines for further information. As for the clinical utility of alternative microbiological methods in the ICU setting, Table 2 displays a summary of the standards for IPA and other clinical forms of aspergillosis. Briefly, alternative methods such as galactomannan-, BDG-and PCRbased techniques are not very reliable for early detection of IPA in blood or serum samples from non-neutropenic patients. The performance of these techniques in respiratory samples is significantly better, particularly the quantitative determination of fungal components in bronchoalveolar lavages.
Treatment of IFDs in the ICU
This section includes the management of IC, candidaemia and IPA in patients in the ICU setting, emphasizing the considerations that should be taken into account when treating critically ill patients. Cuenca-Estrella et al.
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Treatment of invasive candidosis and candidaemia
Early administration of appropriate antimicrobial therapy reduces mortality among septic patients, [24] [25] [26] including those with candidaemia. [27] [28] [29] As Candida is an infrequent cause of bloodstream infections, most empirical regimens do not include antifungal agents, often leading to a delay between the onset of sepsis and administration of effective therapy in these patients.
Early guidelines favoured the use of fluconazole over amphotericin B for treating stable patients with candidaemia, with opinion divided for more severely ill patients. [30] [31] [32] [33] The echinocandins were introduced in 2001 with caspofungin. This was followed soon after with anidulafungin and micafungin. Over time, guidelines have recommended echinocandins as the initial therapy for more severely ill patients with candidaemia 32, 34 and more recently in all patients. 7, 8 As clinical trials allowed up to 2 days of cliniciandirected treatment before enrolment, 30, [35] [36] [37] [38] [39] [40] [41] no echinocandin has ever been compared with fluconazole as initial therapy for candidaemia in a randomized clinical trial. In contrast to published guidelines, registry data and retrospective studies on mortality associated with candidaemia have examined initial therapy; although the results have been inconsistent, the largest have trended towards or significantly favoured fluconazole. [42] [43] [44] [45] [46] [47] [48] [49] [50] The findings that a delay in initiating appropriate treatment is associated with increased mortality and cost in patients with candidaemia 27, 28 has contributed to recent guidelines 7, 8 recommending initiation of empirical antifungal therapy in critically ill patients at high risk of IC. Despite the guideline recommendation, several randomized trials of empirical antifungal therapy in ICU patients at risk of IC showed no benefit, [51] [52] [53] even when colonization was included in the clinical risk model. 53 The current treatment guidelines for patients with documented IC and candidaemia recommend an echinocandin as first-line therapy in patients, with fluconazole as an acceptable alternative for selected patients. 7, 8 In addition to reported improved efficacy with the echinocandins, the guidelines note a favourable safety profile and increasing resistance observed with fluconazole. However, data from randomized controlled trials comparing echinocandin therapy with azole therapy are limited. The echinocandin anidulafungin was compared with fluconazole in patients with IC in a moderately sized randomized controlled study. At the end of intravenous therapy, treatment was more successful in patients treated with anidulafungin, as compared with those receiving fluconazole. 40 Additionally, the all-cause day 60 mortality was numerically but not statistically significantly lower in the patients treated with anidulafungin. In a retrospective analysis of critically ill patients from this trial, those receiving anidulafungin had significantly better responses at the end of therapy compared with fluconazole-treated patients. 54 A combined analysis of Invasive fungal diseases in the ICU JAC ii11 patient-level data from seven prospective randomized trials comparing treatment for candidaemia and IC found that echinocandin therapy was a significant predictor of survival. 55 While prospective randomized trials control for many of the potential biases seen in observational and retrospective studies, they do not evaluate initial therapy. Non-study therapy is allowed to be prescribed while patients are being enrolled. Active surveillance databases and retrospective trials, however, do allow comparisons of initial therapy. Reports supporting the use of initial echinocandin therapy include a Brazilian cohort of patients with candidaemia, where treatment with an echinocandin was associated with a higher probability of survival; however, only a small percentage of patients received initial echinocandin therapy. 42 In a Spanish cohort of patients with candidaemia treated on internal medicine wards, mixed results were observed. Patients treated with early antifungal therapy saw a similar mortality between patients treated with caspofungin or fluconazole, while in patients receiving definitive therapy the mortality was significantly lower with echinocandins compared with fluconazole. 43 Conversely, a North American prospective registry of patients with IFDs found no difference in mortality in patients with IFDs who received IDSA guideline-compliant therapy compared with those who received non-IDSA-compliant therapy. 50 A closer look at patients with candidaemia in the PATH registry who were critically ill (defined as the need for mechanical ventilation) noted a significantly lower mortality in patients receiving fluconazole compared with an echinocandin. 45 In addition, a large Spanish prospective propensity score-matched cohort study in patients with candidaemia found that using fluconazole for either empirical or targeted treatment was not associated with a worse outcome compared with an echinocandin. 46 In a single-centre prospective cohort study in patients with candidaemia, initial therapy with an echinocandin was associated with a greater likelihood of day 30 mortality. 48 Specifically, in patients with bloodstream infections with C. glabrata, a species with increased resistance to fluconazole, survival in patients treated with an echinocandin versus fluconazole was similar. 44 The amphotericin class of antifungal agents are generally felt to have the broadest spectrum of activity and to be fungicidal for most Candida species. However, due to their side effect profile these agents are not used as first-line agents for candidaemia and invasive candidiasis. 7, 8 Amphotericin B deoxycholate is generally reserved for use in resource-limited areas. 8 Liposomal amphotericin has significantly less toxicity than amphotericin B deoxycholate and therefore has a role in select patients with candidaemia and invasive candidiasis, especially if there is intolerance, limited availability or resistance to other antifungal agents. 8 Notably, in a randomized trial of candidaemia and invasive candidiasis liposomal amphotericin had similar outcomes compared with micafungin, albeit with more adverse events. 36 To conclude, the selection of an antifungal therapy for IC and candidaemia should take into account numerous factors including, but not limited to, the dominant Candida species and susceptibility data in a particular clinical unit, the patient's severity of illness, recent significant azole or echinocandin exposure and evidence of deep tissue and organ involvement. While the current guidelines clearly favour an echinocandin as initial therapy in patients with candidaemia, the foundation for these recommendations is quite limited. Failure to consider the initial use of azole therapy will likely lead to overuse of the echinocandin class of antifungal agents, potentially resulting in increased costs, and with downstream problems related to resistance.
Treatment of invasive pulmonary aspergillosis
Approximately 43%-80% of cases of IPA appear in patients without a haematological malignancy admitted to the ICU, although these patients are rarely included in the seminal studies about treatment of aspergillosis. 56 IPA has also been described in apparently immunocompetent patients in a critical condition as a complication of acute respiratory distress syndrome (ARDS), COPD, influenza, pneumonia, burns, severe bacterial infection, liver failure or cirrhosis and malnutrition. [57] [58] [59] These patients frequently do not fulfil the classical EORTC/MSG criteria for IPA.
14 Confirmation of diagnosis may be delayed, resulting in high mortality rates. At the same time, drug-drug interactions and drug toxicity may occur more frequently in these critically ill patients as compared with haematological patients.
There are no current recommendations for IPA prophylaxis in non-neutropenic ICU patients, except in ICU patients after solid organ transplantation (SOT). 60 Targeted prophylaxis is preferred in most SOT recipients with risk factors. Risk factors for early IPA in all SOT recipients, including heart transplants, comprise renal failure requiring renal replacement therapy, re-intervention, cytomegalovirus (CMV) disease and high environmental exposure to mould spores. 61 In liver transplantation, a high Mayo End-stage Liver Disease (MELD) score, transplantation in fulminant hepatic failure, high intra-operative transfusion needs or re-transplantation are considered indications for post-surgical prophylaxis. 62, 63 In lung transplant recipients, risk factors include previous respiratory tract colonization with Aspergillus, single lung transplant, CMV disease and acquired hypogammaglobulinaemia. 64 However, significant variation in practice has been noted. To avoid drug-drug interactions and toxicity, echinocandins or inhaled amphotericin B are preferentially used, although voriconazole has also demonstrated its efficacy and safety in that setting. Duration of prophylaxis is adjusted to the presence of risk factors and, with the exception of lung recipients, is usually limited to 3-4 weeks. 64 Despite no comparative studies of antifungal therapy reported in non-haematological patients, voriconazole is considered firstline therapy for IPA in the ICU setting, as it has been associated with reduced mortality. Amphotericin B is regarded as an alternative to the triazole. 21 Voriconazole is recommended for IPA due to A. fumigatus if the isolate is voriconazole susceptible (susceptible if MIC 1 mg/L), whilst in the case of resistance (MIC .2 mg/L) liposomal amphotericin B therapy is preferred. Where the voriconazole MIC equals 2 mg/L (intermediate) the response to voriconazole monotherapy is unknown. 65 Isavuconazole is currently accepted as an alternative first-line option in both American and European guidelines. 21, 60 Isavuconazole is a new triazole with a long half-life. It has a better side effect profile than voriconazole and demonstrated noninferiority in the treatment of IPA compared with voriconazole.
Importantly, especially in ICU patients, therapeutic drug monitoring (TDM) of voriconazole is used to avoid treatment failure, resistance development and toxicity. TDM is recommended as voriconazole pharmacokinetics are non-linear and drug levels can fluctuate throughout the treatment based on drug-drug interactions and changes in hepatic clearance. This is especially the case Cuenca-Estrella et al.
ii12 in patients with liver insufficiency, as is frequently observed in ICU patients. 66 Several ICU-relevant side effects should be considered when using voriconazole: corrected QT interval prolongation, liver dysfunction and encephalopathy are the most common in the ICU setting. Data supporting routine TDM for isavuconazole are also limited, although from Phase II/III clinical studies trough levels of 2-3 mg/L are suggested. Currently, there is limited evidence to suggest that patients receiving intravenous posaconazole require routine TDM, but TDM could still be useful if the pathogen has elevated MICs or is unresponsive to treatment, or in the event of unexplained toxicity and some patients receiving oral formulations. 21 IPA may affect 0.3% of patients with liver cirrhosis. Both acute liver failure and advanced cirrhosis, mainly alcoholic hepatitis treated with glucocorticoids, have been recognized as risk factors for IPA. A low level of clinical suspicion explains why 53% of the cases of IPA in cirrhotic patients are only recognized post mortem. In those ICU patients with severe liver insufficiency (cirrhosis ChildPugh scores B and C), liposomal amphotericin B is usually the first therapeutic option. 67 Antifungal resistance is not a common problem, although some cases have been reported. In settings with environmental azole resistance, no change to the primary therapeutic regimen for IPA is recommended when resistance rates are ,10%. If azole resistance rates are .10%, first-line therapy with voriconazole plus echinocandin or liposomal amphotericin B is recommended. 68 The use of combination antifungal therapy for IPA is debated, although theoretically this can achieve: (i) potential synergistic effects; (ii) a broader antifungal spectrum; and (iii) potentially a reduction of acquired resistance. 69 In vitro and animal studies demonstrated synergistic or additive effects of a mould-active triazole (itraconazole, voriconazole or posaconazole) or amphotericin B with an echinocandin, but few human studies support this practice. 70 The combination of voriconazole with anidulafungin failed to demonstrate an overall significant difference over voriconazole alone in the primary outcome in IPA cases, although in a post hoc subgroup analysis among galactomannan-positive patients a significant advantage favouring combination treatment was recorded. 70 The use of combination therapy is considered a therapeutic solution: (i) in cases of resistance (e.g. Cyp51a mutations); (ii) in central nervous system aspergillosis due to azole-resistant Aspergillus (favouring flucytosine); (iii) as broad initial coverage pending pathogen identification; (iv) for salvage therapy in refractory disease; and (v) until adequate plasma concentrations of voriconazole can be documented. 21, 71 The duration of IPA treatment ranges between 3 and 50 weeks. Physicians should consider intravenous-to-oral switch in stable patients and, before treatment discontinuation, close monitoring is essential with imaging and microbiological evaluation.
Assessment of treatment response using changes in galactomannan seems to be an attractive strategy for early optimization of therapy. 72 Given the potential long duration of therapy, the availability of tools able to predict response in a timely manner would seem highly relevant.
Conclusions
Conventional microbiological tests continue to be the benchmark of the standards of care to diagnose candidaemia and IC. Because of the limitations of methods based on cultures, alternative techniques have been developed. The quantification of BDG is already recommended in several guidelines. The combination of detection of two or more biomarkers could be of clinical utility for early diagnosis of IC and could become the standard for targeted and pre-emptive therapy. Regarding IPA, alternative methods such as galactomannan-, BDG-and PCR-based techniques are not very reliable in blood or serum samples from non-neutropenic patients. The performance of these techniques in respiratory samples is significantly better and could become the diagnostic standard of care for IPA in the ICU setting.
When considering antifungal therapy for candidaemia and invasive candidiasis, clinicians should consider the dominant Candida species, the susceptibility data in a particular clinical unit, the patient's severity of illness, recent significant antifungal exposure and whether there is evidence of deep tissue and organ involvement. An echinocandin is generally favoured as initial therapy in patients with candidaemia, although azoles may be used in less critically ill patients. Amphotericin B is reserved for use in some clinical areas. Clinicians need to consider the initial use of azole therapy and a rapid switch to oral agents both to decrease costs and decrease problems with resistance.
Regarding the standard of care for IPA, although during the last decade significant therapeutic progress in critically ill patients has been recorded, further investigation is needed. It should assess the incidence of IPA in the ICU setting, the clinical impact of rapid and point-of-care tests and the significance of combination treatment, including patient outcomes and the impact of the pharmacokinetic/pharmacodynamic profile of the combined antifungal molecules. This article forms part of a Supplement sponsored and funded by Gilead Sciences. Editorial assistance was provided by Tribal Healthcare. The content of this Supplement is based on the sessions presented at the CARE X meeting, held in Barcelona in November 2017.
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